Panzilan (Pantoprazole)

Pantoprazole binds irreversibly to the gastric H+/K+‑ATPase (proton pump) on parietal cells, blocking the final step of acid secretion. This inhibition lowers both basal and stimulated gastric acid output, providing symptom relief and allowing damaged mucosa to recover.

The specific dose of Panzilan is determined by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. Dosage recommendations are individualized and should follow the prescriber’s instructions.

Pantoprazole is classified as pregnancy category B in many regions, indicating no evidence of risk in animal studies but limited human data. It should be used during pregnancy or lactation only if clearly needed and after a risk‑benefit assessment by the prescriber.

To request Panzilan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pantoprazole, the active ingredient in Panzilan, shares the core acid‑suppression mechanism of other PPIs such as omeprazole and esomeprazole. Differences lie in pharmacokinetic profiles, drug‑interaction potential, and individual patient tolerance, making pantoprazole a preferred option for patients requiring fewer CYP‑mediated interactions.

Panzilan tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. No refrigeration is required, and the product should be kept out of reach of children.

Panzilan is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically advised.

Serious adverse events, though rare, include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated diarrhea, low magnesium levels, liver enzyme elevations, and interstitial nephritis. Patients should seek immediate medical attention if they experience symptoms such as rash, persistent diarrhea, muscle weakness, or abnormal kidney function.

Panzilan is contraindicated in patients with known hypersensitivity to pantoprazole or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, those on certain interacting medications, and patients with a history of allergic reactions to proton pump inhibitors.